Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787452 | 0.92 | CTSD (0.46) | PLGCTSSCTSKREN | |
| SCHEMBL29787579 | 0.92 | PLG (0.46) | PLGCTSSCTSKRENPSMB1 | |
| SCHEMBL29397682 | 0.88 | PTPN1 (0.54) | PLGCTSSCTSKPTPN1HDAC8 | |
| SCHEMBL11652135 | 0.88 | PTPN1 (0.54) | PLGCTSSCTSKPTPN1HDAC8 | |
| SCHEMBL7057456 | 0.88 | PTPN1 (0.54) | PLGCTSSCTSKPTPN1HDAC8 | |
| SCHEMBL29400153 | 0.88 | PTPN1 (0.54) | PLGCTSSCTSKPTPN1HDAC8 | |
| SCHEMBL9646827 | 0.88 | PTPN1 (0.54) | PLGCTSSCTSKPTPN1HDAC8 | |
| SCHEMBL29787421 | 0.86 | PLG (0.50) | PLGCTSSCTSKRENPTPN1 | |
| SCHEMBL29787407 | 0.86 | PLG (0.48) | PLGCTSSCTSKRENHDAC8 | |
| SCHEMBL29787422 | 0.86 | REN (0.43) | PLGRENPSMB1PSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3127914-B1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVES | UNIV MIYAZAKI (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-20230120030-A1 | Long-Acting Adrenomedullin Derivatives | UNIVERSITY OF MIYAZAKI (JP) | 2023-04-20 | — | — | US | disclosed |
| US-11414474-B2 | Long-acting adrenomedullin derivatives | UNIVERSITY OF MIYAZAKI (JP) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414474-B2 | Long-acting adrenomedullin derivatives | APLNR, NPBWR1, NPPA | PLG 372/4885CTSS 4011/4885CTSK 3792/4885 |
| US-20230120030-A1 | Long-Acting Adrenomedullin Derivatives | APLNR, NPBWR1, NPPA | PLG 372/4885CTSS 4011/4885CTSK 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.